Uğur Şahin, BioNTech CEO (Photo by: Sebastian Gollnow/picture-alliance/dpa/AP Images)

October 2, 2024 03:48 PM EDT

BioNTech opens the hood on its AI ambitions, and they're not just for mRNA

Ryan Cross

Senior Science Correspondent

BioNTech became a big name in biopharma thanks to its Pfizer-partnered Covid-19 vaccine. It’s betting that artificial intelligence will be key to its future. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioNTech opens the hood on its AI ambitions, and they're not just for mRNA

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: After discovering antibiotics with AI, a 31-year-old first-time CEO raises $17M to fight aging

Scoop: Founding CEO leaves Atomwise, casting doubt over a once high-flying AI startup

EMA looks to make its drug approval processes more efficient

Lilly invests $4.5B in new Indiana site to bring clinical manufacturing in-house

J&J and Bayer to lay off almost 300 staffers in New Jersey

3 Tiers for AAV Potency Assay Development Success

BioN­Tech opens the hood on its AI am­bi­tions, and they're not just for mR­NA

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BioNTech opens the hood on its AI ambitions, and they're not just for mRNA